A Predictive Model Based on Bi-parametric Magnetic Resonance Imaging and Clinical Parameters for Clinically Significant Prostate Cancer in the Korean Population.
Bi-parametric magnetic resonance imaging
Nomograms
Prostatic neoplasms
Transperineal prostate biopsy
Journal
Cancer research and treatment
ISSN: 2005-9256
Titre abrégé: Cancer Res Treat
Pays: Korea (South)
ID NLM: 101155137
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
18
10
2020
accepted:
31
12
2020
pubmed:
11
1
2021
medline:
8
2
2022
entrez:
10
1
2021
Statut:
ppublish
Résumé
This study aimed to develop and validate a predictive model for the assessment of clinically significant prostate cancer (csPCa) in men, prior to prostate biopsies, based on bi-parametric magnetic resonance imaging (bpMRI) and clinical parameters. We retrospectively analyzed 300 men with clinical suspicion of prostate cancer (prostate-specific antigen [PSA] ≥ 4.0 ng/mL and/or abnormal findings in a digital rectal examination), who underwent bpMRI-ultrasound fusion transperineal targeted and systematic biopsies in the same session, at a Korean university hospital. Predictive models, based on Prostate Imaging Reporting and Data Systems scores of bpMRI and clinical parameters, were developed to detect csPCa (intermediate/high grade [Gleason score ≥ 3+4]) and compared by analyzing the areas under the curves and decision curves. A predictive model defined by the combination of bpMRI and clinical parameters (age, PSA density) showed high discriminatory power (area under the curve, 0.861) and resulted in a significant net benefit on decision curve analysis. Applying a probability threshold of 7.5%, 21.6% of men could avoid unnecessary prostate biopsy, while only 1.0% of significant prostate cancers were missed. This predictive model provided a reliable and measurable means of risk stratification of csPCa, with high discriminatory power and great net benefit. It could be a useful tool for clinical decision-making prior to prostate biopsies.
Identifiants
pubmed: 33421975
pii: crt.2020.1068
doi: 10.4143/crt.2020.1068
pmc: PMC8524004
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1148-1155Subventions
Organisme : College of Medicine, Korea University
Références
Prostate Cancer Prostatic Dis. 2018 Apr;21(1):57-63
pubmed: 29259293
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):88-93
pubmed: 31239513
Cancer Res Treat. 2020 Jul;52(3):714-721
pubmed: 32054151
Eur Urol Oncol. 2019 Sep;2(5):490-496
pubmed: 31412016
JAMA Oncol. 2018 May 1;4(5):678-685
pubmed: 29470570
BJU Int. 2015 Mar;115(3):381-8
pubmed: 24447678
Radiology. 2017 Nov;285(2):493-505
pubmed: 28727544
Urology. 2002 Jun;59(6):797-802
pubmed: 12031356
JAMA Netw Open. 2018 Jun 1;1(2):e180219
pubmed: 30646066
Eur Urol. 2012 Apr;61(4):652-61
pubmed: 22134009
Eur Radiol. 2020 Oct;30(10):5404-5416
pubmed: 32424596
Urology. 2006 Apr;67(4):762-8
pubmed: 16600352
Crit Rev Oncol Hematol. 2017 Dec;120:180-193
pubmed: 29198331
Eur Urol. 2019 Apr;75(4):570-578
pubmed: 30477981
Eur Urol. 2010 Jan;57(1):79-85
pubmed: 19733959
Eur Urol. 2019 Feb;75(2):310-318
pubmed: 30082150
BJU Int. 2017 Dec;120(6):774-781
pubmed: 28207981
J Magn Reson Imaging. 2017 Oct;46(4):1089-1095
pubmed: 28165653
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986955
Eur Urol. 2017 Dec;72(6):888-896
pubmed: 28400169
Cancer Treat Res. 2018;175:55-86
pubmed: 30168117
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):101-109
pubmed: 30127462
Eur Urol. 2018 Apr;73(4):572-582
pubmed: 29129398
BJU Int. 2020 Mar;125(3):407-416
pubmed: 31758738
BMJ. 2016 Jan 25;352:i6
pubmed: 26810254
Prostate Cancer Prostatic Dis. 2019 May;22(2):331-336
pubmed: 30413806
Transl Androl Urol. 2018 Feb;7(1):18-26
pubmed: 29594016